- Home
- MSM vs ABVX Comparison
MSM vs ABVX Comparison
Compare MSM & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSM
- ABVX
- Stock Information
- Founded
- MSM 1941
- ABVX 2013
- Country
- MSM United States
- ABVX France
- Employees
- MSM N/A
- ABVX N/A
- Industry
- MSM Industrial Machinery/Components
- ABVX
- Sector
- MSM Industrials
- ABVX
- Exchange
- MSM Nasdaq
- ABVX Nasdaq
- Market Cap
- MSM 4.7B
- ABVX 5.3B
- IPO Year
- MSM 1995
- ABVX N/A
- Fundamental
- Price
- MSM $92.35
- ABVX $88.89
- Analyst Decision
- MSM Hold
- ABVX Buy
- Analyst Count
- MSM 5
- ABVX 7
- Target Price
- MSM $90.60
- ABVX $74.86
- AVG Volume (30 Days)
- MSM 388.1K
- ABVX 999.1K
- Earning Date
- MSM 10-23-2025
- ABVX 08-11-2025
- Dividend Yield
- MSM 3.69%
- ABVX N/A
- EPS Growth
- MSM N/A
- ABVX N/A
- EPS
- MSM 3.54
- ABVX N/A
- Revenue
- MSM $3,743,630,000.00
- ABVX $11,444,012.00
- Revenue This Year
- MSM N/A
- ABVX $25.23
- Revenue Next Year
- MSM $4.36
- ABVX N/A
- P/E Ratio
- MSM $26.06
- ABVX N/A
- Revenue Growth
- MSM N/A
- ABVX 128.98
- 52 Week Low
- MSM $68.10
- ABVX $4.77
- 52 Week High
- MSM $92.68
- ABVX $86.07
- Technical
- Relative Strength Index (RSI)
- MSM 61.57
- ABVX 87.25
- Support Level
- MSM $88.48
- ABVX $78.00
- Resistance Level
- MSM $92.00
- ABVX $78.49
- Average True Range (ATR)
- MSM 1.76
- ABVX 3.31
- MACD
- MSM 0.26
- ABVX -0.49
- Stochastic Oscillator
- MSM 86.93
- ABVX 84.94
About MSM MSC Industrial Direct Company Inc.
Founded in 1941, MSC Industrial Direct originally manufactured and sold cutting tools to metalworking shops in New York. Through a series of acquisitions and organic expansions, MSC has grown into an industrial distribution powerhouse with a focus on specialized metalworking products and services. The firm also distributes a wide breadth of maintenance, repair, and operations (MRO) supplies. MSC primarily operates within North America where it derives over 95% of its revenue.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.